Oxford Endovascular secures £8m in Series A+ funding led by Parkwalk Advisors to advance brain aneurysm treatment
Parkwalk Advisors spearheaded the round to help the medical technology company prepare for human trials.
Share allotment filed at Companies House
Oxford Endovascular is a medical technology company developing origami-inspired medical devices to treat brain aneurysms.
Oxford Endovascular has secured £8m in a Series A+ funding round led by Parkwalk Advisors to advance its brain aneurysm treatment towards human trials. The company develops the OXIFLOW flow-diverter stent, which uses origami-inspired design principles to improve precision during procedures.
Parkwalk Advisors contributed £4.2m to the round. Additional participants included Norcliffe Capital, Oxford Science Enterprises, Vulpes Investment Management, and the University of Oxford.
The capital will support the company as it prepares for First-In-Human clinical trials and expands its operations. The technology addresses a significant clinical need for a condition affecting a large portion of the population.
From the founder
"With the support of our investors, we are on the cusp of revolutionising brain aneurysm treatment. Our team is dedicated to working with regulators, medical professionals, and industry experts to bring this product to market and address a condition impacting countless individuals worldwide."
Mike Karim
CEO at Oxford Endovascular
Investor perspective
"This is a device we’ve supported since its early stages, and it has the potential to improve lives. It exemplifies the exceptional ideas emerging from UK universities."
Alun Williams
Investment Director, Parkwalk Advisors
Use of funds
- 01Expand into international markets
Investors
Alun Williams
Parkwalk Advisors
Norcliffe Capital
Oxford Science Enterprises
Vulpes
University of Oxford
Categories
About the company
Oxford Endovascular
Oxford Endovascular develops origami-inspired medical devices for brain aneurysm treatment.